The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has emerged over the past two decades.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...

Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first line of treatment is often hormone therapy, which is very good at slowing or stopping the cancer — ...

Early-stage prostate cancer is very treatable with surgery and radiation therapy. Once the cancer spreads, it becomes harder to stop. Late-stage prostate cancer treatments like chemotherapy and ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...

Prostate cancer treatment, particularly hormone therapy, significantly disrupts sleep, leading to fatigue and reduced daytime ...